Hello and welcome to the PacBio First Quarter 2024 Earnings Conference Call. As a reminder, this conference is being recorded. I would now like to hand the call to Todd Friedman, Senior Director of Investor Relations. Please go ahead.

Good afternoon, and welcome to PacBio's first quarter 2024 earnings conference call. Earlier today, we issued a press release outlining the financial results we will be discussing on today's call, a copy of which is available on the Investors section of our website at www.pacb.com or as furnished on Form 8-K available on the Securities and Exchange Commission website at www.sec.gov. A copy of our earnings presentation is also available on the Investors section of our website at www.pacb.com. With me today are Christian Henry, President and Chief Executive Officer; and Susan Kim, Chief Financial Officer. On today's call, we will be making forward-looking statements, including statements regarding predictions, progress, estimates, plans, intentions, guidance, and others, including expectations with respect to our growth potential, instrument and consumable sales, our commitment to create a sustainable cash flow positive company by the end of 2026, expectations with respect to certain customers being early in the ramp-up and measures to increase their utilization, GAAP and non-GAAP guidance and expected benefits of using PacBio products or technologies and new product expectations. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause our actual results to differ materially from those projected or discussed. We refer you to the documents that we file with the SEC, including our most recent Forms 10-Q and 10-K, and our recent press release to better understand the risks and uncertainties that could cause actual results to differ. We disclaim any obligation to update or revise these forward-looking statements except as required by law. We will also present certain financial information on a non-GAAP basis. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company's operating results as reported under U.S. GAAP. Management believes that non-GAAP financial measures, combined with U.S. GAAP financial measures, provide useful information to compare our performance relative to forecasts and strategic plans, and benchmark our performance externally against competitors. Reconciliations between historical U.S. GAAP and non-GAAP results are not presented in tables within our earnings release. For future periods, we are unable to reconcile the non-GAAP gross margin and non-GAAP operating expenses without unreasonable efforts due to the uncertainty regarding, among other matters, certain acquisition-related items that may arise during the year, including future changes in fair value adjustments of contingent consideration and allocation of amortization expense attributable to certain acquired intangible assets. Please note that today's call is being recorded and will be available for replay on the Investors section of our website shortly after the call. Investors electing to use the audio replay are cautioned that forward-looking statements on today's call may differ or change materially after the completion of the live call. Finally, we will be hosting a question-and-answer session after our prepared remarks. We ask that analysts please limit themselves to one question so we could accommodate everybody in the queue. I'll now turn the call over to Christian.

Thank you, Todd, and thank you for joining our call today. In today's remarks, we will discuss some of the factors that contributed to our previously announced revenue shortfall and revised full-year guidance. We will also discuss the steps we are taking to return to revenue growth and why we are confident in the assumptions underlying our updated financial forecasts. Finally, we will share our refocused priorities for 2024, which we believe will position us to build PacBio into a sustainable, cash-flow-positive company with the ability to execute in any macro environment. While we forecast near-term growth to be lower than our original guidance for 2024, we have never been more confident in the value of our platforms, our long-term growth potential, and our ability to capture market share in the multi-billion dollar sequencing opportunity. But first, let's recap the first quarter. Consistent with our pre-announcement on April 16, revenue of $38.8 million for the first quarter was below expectations due to an increasing number of customers delaying instrument purchases and softness in consumable shipments. Based on the first-quarter results and our expectation that some of these external factors will likely persist throughout 2024, we expect full-year revenue to be in the range of $170 million to $200 million. The instrument shortfall primarily resulted from elongated customer purchasing cycles, as the median sales cycle for Revio instrument purchases increased more than we expected in the first quarter of 2024. More specifically, we believe that the sales cycle increased primarily because of uncertainty surrounding the timing of funding for new capital equipment, particularly in the United States and China, smaller Sequel II and IIe customers who are planning to upgrade to a Revio are waiting for the samples to drive that upgrade, and an increasing proportion of the sales pipeline is comprised of new customers in the first quarter of 2024, which have proven to have longer sales cycles compared to those existing PacBio customers. While consumable revenue grew 15% year-over-year, it was also below our expectations. We believe this was primarily attributed to the slower-than-expected ramp-up in sequencing by our small and mid-sized customers, many of whom are new to PacBio; the time for new Revio customers and new projects to reach full capacity has been slower than we anticipated; sample delays impacting sequencing volume in the quarter for certain large customers; and some smaller service providers in China operating at lower utilization as a result of the challenging funding environment. In Q1, more customers than we expected utilized their Revio systems at less than 20% capacity. Many of these are newer customers and the average age of the systems in this category was less than four months, which we believe indicates that these customers are still early in their ramp-up. The pace of the ramp is dependent on a number of factors including, the timing of sample availability, lab readiness, and funding, among other reasons. We are putting measures in place that we believe will help these customers ramp to their full utilization as timely as possible, and help drive consumable growth going forward. Moving on, we are implementing several strategies aimed at accelerating instrument and consumable revenue. First is an intense focus on the customer to drive new sales opportunities, close existing deals, and accelerate consumable revenue ramp-up time. And among other activities, this involves launching our PRISM customer-focused roadshows. These events include discussions and workshops with PacBio users and key opinion leaders in genomics where they'll engage and share the groundbreaking science that Revio is enabling. We're organizing events across six global cities with approximately 1,000 registered attendees representing over 500 organizations many of whom we believe will become future Revio users. We're reducing the stands and layers in the commercial organization, which will allow leadership to get closer to and more involved in the sales process. We're also establishing tiger teams to actively work with low-volume customers to accelerate their Revio ramp and collaborate with them to secure samples to feed their sequencer, and we're continuing to collaborate with customers to demonstrate the value of HiFi long-read sequencing to drive long-term durable revenue. Second, we're addressing the upfront CapEx barrier some customers face when assessing HiFi, and we're doing this by implementing promotions that ease customers' upfront CapEx requirements and we're doing this in ways that preserve PacBio's overall economic value. These promotions have already created more funnel opportunities, which we believe will close this year, and we're focusing our product development on a benchtop platform, which will allow for a lower CapEx entry and upon launch, potentially open up PacBio HiFi sequencing to hundreds of new global customers. Third, we're expanding the market and applications addressable with Revio and HiFi. As I'll discuss shortly, we are investing in developing library prep and informatics solutions around Revio that enhance the platform's value proposition. These launches include PureTarget for targeted clinical research applications and Kinnex for transcriptomics and 16S metagenomics, and we're also developing future enhancements that we believe will further reduce DNA input requirements below one microgram of DNA for a 30x whole human genome, potentially opening up more existing samples and new projects to HiFi sequencing. Looking ahead, our pipeline of sales leads has continued to grow each quarter since we launched Revio. We believe our current sales pipeline is sufficient to at least support the midpoint of our guide of 120 Revio systems, which provides further confidence in our revised revenue targets for 2024. There's no doubt that PacBio and our industry are facing increasing headwinds this year. However, we remain incredibly optimistic about our business and the prospects for long-read sequencing. Our powerful sequencing technologies continue to play an important role in revolutionizing genomics, and the demand for and interest in our products indicates the tremendous market opportunity ahead. One encouraging indicator is the amount of data customers generate with their sequencers. Growth in this metric demonstrates increasing utility and broader acceptance of long-read HiFi technology. In the first quarter, total data generated from PacBio long-read sequencers grew 2.5x from the first quarter of last year. This growth is a testament to the overall interest in Revio and the continued market share gain for long-reads. As of March 31st, just over one year after commercialization, we surpassed 200 cumulative Revio shipments, marking the fastest installed base ramp in PacBio history. From a throughput perspective, this has the same power as over 3,000 Sequel IIe's, our previous generation platform. This rapid scale-up demonstrates our customer's desire to sequence using PacBio HiFi more than ever, but it will take some time for them to migrate projects and samples to this newfound capacity. We've been exceptionally pleased with the number of new customers adopting Revio, as 57% of the systems shipped in the first quarter went to new PacBio instrument customers. These customers included the University of Tartu, host of Estonia's National Biobank. The team selected Revio exclusively over other short and long-read technologies to sequence 10,000 whole human genomes as part of their goal to adopt personalized medicine at scale and understand the underlying genetics of health, disease, and treatment outcomes. It also includes the first Revio in Latin America which will be used by a customer in support of a 1,000-sample human genome project. These new Revio customers add to the existing multi-thousand sample projects that we've shared over the past year, such as large-scale human genomics program in Singapore which is expected to start sequencing this quarter and continued sequencing for the All of Us and Million Veterans Program in the United States. We're also pleased to announce that Ambry Genetics has joined the collaboration with the GREGoR consortium and the University of California, Irvine and aims to sequence up to 7,000 long-read HiFi genomes over the next three years, focusing on developing new insights into rare disease etiology and treatment. Revio enables more than just large-scale research studies. Hospitals are increasingly seeking to implement Revio to achieve unprecedented insights into genetic and rare disease. It includes existing PacBio customers like Seoul National University Hospital, which utilized one of our recently-announced instrument promotions and plans to use HiFi long-read technology to improve its testing capabilities in rare disease and cancer. Also, a leading pediatric hospital in Canada purchased a Revio; its first PacBio system to sequence 1,500 rapid whole genomes of critically ill infants. HiFi was the clear choice for this clinical-oriented customer as the other long-read sequencing technology proved too high in error rate. To support these customers, we are continuously enhancing our software, launching new library prep, and sample prep solutions which make PacBio sequencing more turnkey and more accessible than ever. Additionally, we believe these new products will help contribute to a recurring revenue stream outside the core SMRT cells and sequencing reagents used to run Revio. We've seen tremendous interest in our recently launched Kinnex full-length RNA kits. Launched in the fourth quarter of 2023, we've booked orders for 160 customers as of March 31, totaling over $1.5 million. The PacBio PureTarget panel was launched and began shipping in late March, allowing for comprehensive characterization of repeat expansions. Expansions of repetitive DNA sequences have been linked to over 50 monogenic disorders and cancers. This kit enables customers to interrogate some of the most critical and hard-to-sequence genes related to these diseases and multiplex up to 192 samples on the Revio system. Combined with our TRGT repeat expansion caller and Nanobind DNA extraction kit, it allows for an easy and scalable workflow to capture repeat expansions, bringing customers from sample to answer in three days. We just started shipping these kits in March, and we are already seeing great interest from customers ranging from pediatric hospitals to large commercial testing labs, biopharma, and academic labs. Launched in the first quarter, our HiFi Prep and Plex library kits further enable our customers to automate and scale on Revio. These kits allow Revio customers to prepare up to 96 libraries at a time at a lower cost per library, and some of our largest customers are adopting these kits to help them further scale their projects. We expect the kits to be particularly beneficial for microbial genome and low-pass large genome sequencing, where library prep costs are a large percentage of the overall workflow cost. The Nanobind PanDNA kit developed from the Circulomics technology supports a high molecular weight extraction from cells, bacteria, blood, tissue, insect, and plant nuclei. This new product consolidates the capabilities of our existing sample-specific offerings into a single solution for DNA extraction. Since we acquired it in 2021, over 1,000 customers have ordered Circulomics kits. This product line helps us deliver solutions to the thousands of lower throughput long-read users and can potentially serve as a funnel for our future benchtop long-read sequencer. We continue to be pleased with the traction of our sample extraction offerings, and excluding large OEM purchases from one customer, the first quarter was our most successful quarter for sample prep. Finally, our Version 13 Software continues to improve the Revio user experience. Nearly all customers are utilizing the recently launched adaptive loading feature, which improves customer experience by preventing overloading of the SMRT cell, allowing customers to load DNA more confidently and achieve higher and more consistent yields. With V13 enabled on almost every Revio, the mean yield per SMRT Cell for whole genome sequencing runs in 2024 is approximately five gigabases higher than in 2023. We continue to see success with our Onso platform. Instrument shipments grew again in the first quarter, and the installed base now spans six continents. We've completed our consolidation of Onso instrument and consumable manufacturing into our Menlo Park facility, which allows us to fully leverage our operational infrastructure. So now, let's look ahead and discuss our four strategic priorities going forward. First, improving our commercial execution to drive adoption of both Revio and Onso. We are placing a greater focus on the value proposition of HiFi sequencing and increasing collaboration with customers, purchasing departments, and decision-makers. We are also working to improve our partnership with customers, post-instrument purchase, to ensure that they are getting samples into their lab to feed their Revio. With respect to Onso, in the first quarter, we scaled the manufacturing of the platform, enabling us to deliver instruments based on demand much more rapidly, which will help drive our ability to sell the system. Additionally, we've identified opportunities to drive manufacturing improvements and lower the unit cost of consumables, which gives us the flexibility to lower the list price on Onso flow cells and reagents to as low as $8 per gigabase. With these advances, along with a more focused and targeted selling effort, we believe that we can be very competitive in this market. Second, continuing the development of new platforms that are expected to broaden our product offering and drive our revenue growth. We continue to believe that developing a multi-platform portfolio is important for our success, enabling us to reach more customers and drive technology adoption. While we expect the Revio platform to be the primary contributor to revenue over the next few years, we are aggressively pursuing the development of a long-read benchtop system, which will have a much lower capital cost, enabling us to reach a new subset of lower throughput customers and provide flexibility to existing Revio customers through fleet expansion. We believe that this instrument will address a market of over 1,000 potential customers. We are also developing a high-throughput short-read platform that is expected to enable us to serve high-throughput labs with our leading Sequencing by Binding technology. This highly accurate technology is perfect for needle-in-a-haystack applications such as liquid biopsy. We believe it will be highly competitive in terms of both throughput and cost relative to other high-throughput offerings. The addressable market for this platform is estimated to be over $1 billion per year. We are also continuing to develop our next generation SMRT Cell. This cell is expected to power a new, extremely high-throughput long-read platform, enabling throughput dramatically higher than that of the Revio system. Third, we're implementing projects to improve our gross margin and drive manufacturing efficiencies. A cornerstone of our path to cash flow breakeven is our ability to improve gross margins through revenue mix and unit cost reduction. We've already reduced the production cost of both the Revio instrument and a 25M SMRT Cell and expect more improvements this year and beyond. Outside of our next-generation platforms, this is a critical R&D and operations effort that we will continue to invest in. Finally, we're reducing annualized run-rate operating expenses. Last week, we began implementing our restructuring plan to reduce operating expenses. As part of that, we made the difficult decision to reduce our total headcount by approximately 25%, or 195 employees, and close our San Diego office. Virtually all functions within the company were impacted. The reductions are being made based on our refocused priorities that I discussed above. As a result, I believe that we have the resources required to achieve our near-term priorities. With these reductions, along with other non-headcount related savings, we now expect to lower our non-GAAP operating expenses on an annualized run rate basis by more than a $75 million reduction by year-end. This is above the range we provided in our pre-announcement on April 16. We believe that it positions us to deliver on our commitment to our plan to create a sustainable, cash-flow-positive company by the end of 2026 and enable us to continue to provide scientists with some of the best technologies that push the boundaries of biological discovery. And with that, I'll pass the call to Susan to discuss our financials.

Thank you, Christian. As previously mentioned, we reported $38.8 million in product, service, and other revenue in the first quarter of 2024, compared to $38.9 million in the first quarter of 2023. Instrument revenue in the first quarter was $19.0 million, a decrease of 8% from $20.7 million in the first quarter of 2023. The decrease was due to lower Revio unit shipments. We ended the quarter with an installed base of 201 Revio systems. Turning to consumables, we delivered revenue of $16.0 million in the first quarter, a 15% increase from $14.0 million in the first quarter of last year. Approximately 69% of consumable revenue came from Revio systems, which reflected an annualized pull-through of the Revio system of $254,000 and the remaining consumable revenue from other systems and other consumables. We expect Sequel II and IIe's share of total consumables to continue declining as we continue shipping Revio and customers transition to the new system. Finally, service and other revenue was $3.8 million in the first quarter compared to $4.2 million in the first quarter of 2023. The decline was primarily due to customers transitioning to the Revio systems, which includes a first-year warranty, and opting not to renew their Sequel II/IIe service plans. From a regional perspective, revenue in the Americas was $17.7 million, a 7% decrease compared to the first quarter of 2023. This was driven by a decline in Revio shipments as Revio systems sales took longer to close. We believe the majority of Revio system opportunities that slipped out of the first quarter pipeline encountered challenges with funding. Consumable growth in the quarter was partially offset by delays in large project spending and sample availability at high-utilization sites. For Asia Pacific, revenue was $12.8 million, up 7% versus the prior year with headwinds in China partially offsetting growth in other countries, including Japan. We believe China Revio sales were impacted by capital funding challenges and lower Revio sequencing pricing offered by large service providers, delaying the need to directly purchase Revio instruments by the smaller labs. Looking ahead, we're encouraged by new modernization initiatives in China. We believe these will boost R&D capital spend, including sequencing instruments, as several potential customers have already applied for Revio funding under this program, albeit it's too soon to factor this into our 2024 expectations. Finally, EMEA revenue was $8.4 million, up 6% over the prior year period, but was lower than previously anticipated as some instrument deals were delayed and for some new system orders shipped, the associated consumable orders were pushed to the following quarter after installation. Moving down the P&L, a GAAP gross profit of $11.3 million in the first quarter of 2024 represented a gross margin of 29% compared to a GAAP gross profit of $9.8 million in the first quarter of 2023, which represented a gross margin of 25%. First quarter 2024 non-GAAP gross profit of $12.6 million represented a non-GAAP gross margin of 33%, compared to a non-GAAP gross profit of $9.9 million or 26% in the first quarter of last year. Non-GAAP gross profit in the first quarter excludes approximately $1.3 million of expenses for the amortization of acquired intangible assets. Gross margin increased year-over-year primarily due to adjustments of approximately $3.5 million recognized in the first quarter of 2023 primarily related to excess Sequel II/IIe consumables inventory that resulted from a faster-than-expected decline in demand for Sequel II/IIe due to the product transition to Revio. We are pleased to have completed the consolidation of our short-read consumable manufacturing for reagents and flow cells from San Diego to Menlo Park during the quarter, helping to lower production costs for every consumable kit we manufacture starting in Q2 2024. In addition, we transitioned the build of a key component on the Revio system in-house, which, since being implemented in March, has helped reduce the contract manufacturing overhead expenses on each Revio instrument built by tens of thousands of dollars. GAAP operating expenses were $92.6 million in the first quarter of 2024 compared to $101.0 million in the first quarter of 2023. Non-GAAP operating expenses were $87.2 million in the first quarter of 2024. This represents a 2% decrease from non-GAAP operating expenses of $88.7 million in the first quarter of 2023. Operating expenses in the first quarter included non-cash share-based compensation of $17.4 million, compared to $16.0 million in the first quarter of last year. Regarding headcount, we ended the quarter with 787 employees compared to 796 at the end of 2023 and 793 at the end of the first quarter of 2024. As a reminder, in April, we began implementing reductions in our headcount by approximately 195 employees and, therefore, expect to end the second quarter and full-year 2024 with a headcount of less than 600. GAAP net loss in the first quarter of 2024 was $78.2 million, or $0.29 per share, compared to a GAAP net loss of $88 million in the first quarter of 2023, or $0.36 per share. Non-GAAP net loss was $71.4 million, representing $0.26 per share, in the first quarter of 2024, compared to a non-GAAP net loss of $75.5 million, representing $0.31 per share in the first quarter of 2023. Turning to our balance sheet items. We ended the first quarter with $561.9 million in unrestricted cash and investments, compared to $631.4 million on December 31, 2023. Inventory balances increased in the first quarter to $67.3 million, representing 1.7 inventory turns, compared to $56.7 million on December 31, 2023, representing 2.9 inventory turns. The increases in inventory primarily reflect purchases of Revio and Onso instruments and consumables inventory. Accounts receivable decreased in the first quarter to $30.3 million compared with $36.6 million at December 31, 2023. Now, to expand a bit on our financial guidance. Consistent with our pre-announcement on April 16, we believe full-year 2024 revenue to be between $170 million and $200 million. At the midpoint of this guidance, we assume $85 million of instrument revenue, which includes 120 Revio shipments making Revio still the fastest-growing sequencer in PacBio history. We expect $80 million in consumable revenue, which assumes an annual pull-through of $290,000 for the Revio platform. Moving down the P&L to gross margin, we now expect full-year gross margin to be between 35% and 38%, lower by 1 point at the midpoint from our prior guidance due to lower volumes and revenue. We have made significant progress on improving the per unit cost of both Revio instruments and Revio consumables and expect to end the year with Revio instrument costs 10% lower than when we launched the platform and consumable unit costs over 25% lower. These costs and operational improvements will continue beyond 2024 and are expected to drive quarterly gross margin expansion this year and going forward. Moving to operating expenses, we now expect non-GAAP operating expenses to decline year-over-year from the $355 million we reported in 2023, and be approximately $300 million to $310 million. Specifically, at the midpoint, we expect $150 million in non-GAAP research and development expenses and $155 million in non-GAAP selling, general and administrative expenses. As mentioned, we expect the non-GAAP annualized amount of these savings to be above the high end of our $50 million to $75 million range by year end, and, as a result, we expect full-year non-GAAP operating expenses to decline in 2025 compared to 2024. We continue to expect $5 million to $10 million in interest and other income, 273 million in weighted average shares outstanding for the full-year 2024, and we continue to expect ending cash, cash equivalents, and investments to be in the range of $435 million to $450 million, representing a cash burn of $189 million at the mid-point. As a reminder, we announced that we were unlikely to achieve our previous long-term guidance. While we are not providing updated figures today, we remain committed to our plan of turning the business cash flow positive by the end of 2026 under various revenue scenarios, which include revenue growth in 2025 and beyond with new products and growing consumables off increasing Revio installed base, expanding gross margins with reduced manufacturing per unit costs and continued mix shift to consumables, and lower non-GAAP operating expenses in 2025 compared to 2024 with minimal growth thereafter. We will provide more details behind our assumptions and our updated long-term guidance at a later date. I'll now turn it back to Christian for some final remarks.

Before we move to Q&A, I just wanted to leave you with three things I hope you take away from our call. One, our business and industry are facing headwinds, which we believe are short-term. Two, we have a clear plan to address these issues, which includes proactively working with our customers and focusing our talented people and resources on our highest-potential technologies. It also involves right-sizing our organization and expenses to align with the lower near-term revenue expectations. We are also firmly committed to our plan of achieving positive cash flow exiting 2026. And finally, we remain optimistic about our technology and the power of our differentiated platforms. We are confident that we have the right plan in place that will enable us to capitalize on the long-term growth and value-creation opportunity ahead of us for the benefit of scientists and clinical researchers around the world. We continue to be energized by countless stories of customers utilizing our technologies to look deeper into the genome and uncover biological insights that are otherwise undetectable. With that, I'd like to open the call up to Q&A. Operator?

Today's first question comes from Kyle Mikson with Canaccord.

So Christian, a few years ago you set these really exciting medium-term growth and margin targets, right? And since then, you've had to withdraw those. You just went over that. You're probably not going to come close to hitting those numbers. I think you probably seem confident on cash breakeven, but we'll see what happens there. So definitely, there's been some external factors. A lot of it seems to be due to changes in the Revio forecast, maybe some of the other products as well that you plan on watching. I guess Christian, just how do you kind of regain investor confidence and support in both the demand for the Revio as well as these future long-read sequencers as well as PacBio's ability to provide appropriate and achievable financial guidance going forward?

Thank you for the question, Kyle. Regaining investor confidence is a top priority for us. The first step we've taken is acknowledging that our revenue trajectory has not met our forecasts. We've acted swiftly to adjust our spending to ensure we can affirm our commitment to being cash flow positive by 2026. As Susan mentioned, we anticipate revenue growth, but we believe we can achieve positive cash flows with only modest revenue increases from this point onward. It’s important to understand that we are not aiming for overly ambitious targets for cash flow positivity. We intend to be disciplined in aligning our expenses with our revenue growth. Secondly, our strategy remains focused on developing leading long-read technologies while also building our short-read business. We continue to see significant excitement and adoption of our long-read technologies. This quarter, we generated 2.5 times more sequencing data than we did a year ago, which is a remarkable indicator of our progress compared to our competitors. We're concentrating on translating that excitement into revenue by working closely with our customers to shorten their purchasing cycles in light of the current macroeconomic conditions. This is why we've introduced promotional programs to lower capital expenditure needs. It's worth noting that these promotions maintain our economic position; the impact is primarily a timing issue for our cash flows. We’re lowering the barriers for customers to access our technology. Ultimately, regaining investor confidence is about demonstrating financial discipline, showcasing market leadership, and delivering expected revenues while improving gross margins and achieving profits and positive cash flow. We have significant work ahead of us, but we are excited about our direction. Although it is frustrating and disappointing to make such significant adjustments, acting early gives us a strong chance to achieve positive cash flows.

The next question comes from Dan Brennan with TD Cowen.

Maybe a two-part question. First, Christian, PacBio has been developing long-read technology for over 10 years, and you have a unique position in this field. The Revio has generated significant excitement in the marketplace. Given the current state of your balance sheet, the stock price, and the opportunities in long-read technology along with the increasing demand, I wonder why you remain heavily invested in the short-read portfolio. Onso has shown unique accuracy, but we are unsure of its performance metrics, while you continue to focus on high throughput. Considering the company's challenges and the potential with long-read technology—not just with Revio but also mid throughput—I'm curious why you don’t consider scaling back on short-read to boost investor confidence in achieving positive free cash flow. The second part of my question is about Revio. As we look towards this year and next regarding placements, could you provide any insights into your go-to-market strategy and how you plan to ensure growth in placements?

Yes, Dan, thank you for your question. We've been carefully considering how to manage our business given our financial situation and the current market conditions. The good news is that we have $562 million in cash on our balance sheet, which means we are well-capitalized. We have a strong business with leading technologies in both long-read and short-read areas, and we see many assets and opportunities ahead. The short-read market is certainly more competitive than ever, and we have had to evaluate whether to continue our efforts there. Recently, we scaled up our production capabilities for the Onso systems, leading to increasing shipments each quarter. However, we faced some manufacturing constraints and had late-stage developments to enhance our chemistry. We're still at the beginning of this opportunity. Customers are excited about testing the accuracy of our products and are showing interest, but we have not yet met their demand. Therefore, we're focusing on aggressively driving our marketing and commercialization efforts for Onso without compromising our commercialization opportunities for Revio. We plan to market the product extensively over the next several quarters to gauge its performance. Regarding short-read high-throughput technology, I’m very encouraged by our progress with Apton. We're sequencing billions of reads with high accuracy, and we've been exploring new optical systems for super-high-resolution imaging, which will enhance our sequencing capabilities significantly. Potential customers have been visiting our office to evaluate the Apton technology, and they are eager to get early access machines after reviewing the data. This indicates that we are early in this journey, particularly in niche applications that are crucial for us. I believe we possess the necessary resources to execute on this portfolio, even after recent reductions, and we will closely monitor our market performance in the upcoming quarters and reassess at the end of the year. On the topic of Revio and driving demand, as I mentioned earlier, the sales funnel has been growing each quarter, but the sales cycle has lengthened, especially for new customers who are taking 9 to 12 months to reach a purchase decision. This duration was longer than we anticipated. We are exploring ways to lower entry barriers through capital solutions and improving proof cases via our PRISM events to engage more customers. We have active marketing strategies and direct discussions to assist new customers in shortening their sales cycles. Additionally, we are helping customers who are already in the middle of the market by providing more samples for their Revio systems to increase utilization as they prepare to purchase a second unit. We still have several Sequel IIe instruments available for potential sales, and we are optimistic that our capital reduction plans will help unlock some demand sooner rather than later. Thank you for your question, Dan.

The next question comes from Doug Schenkel with Wolfe Research.

Listen, it was a tough start to the year and you had to make some tough decisions quickly. So I hope you know that is appreciated. It's always tough to start the year this way. And I appreciate you moving quickly. With that in mind, it's good to hear that you think you can get to cash flow breakeven in 2026. And maybe this is asking Dan's question a different way or just trying to take it up a level. But if I oversimplify things a little bit, you kind of got 2 levers. You cut costs or you try to kind of grow into the infrastructure that you built. And it seems like you've kind of veered now to the former, cutting cost. But that ultimately hurts your ability to kind of scale up to be a bigger company. And there's a toggle between those things, right? And what I don't hear is kind of a pruning of the portfolio. So I'm trying to figure out how do you cut costs and how do we balance that. We want you to do that, but if you're cutting costs and you're not pruning the portfolio, simply put, it kind of feels like you're still trying to thread the needle a little bit. And if you're not investing as much and you don't have as much infrastructure, it kind of just hurts the probability of success with essentially everything other than Revio, I think. So help us understand, Christian, maybe I'm wrong, but if I'm not, is this a sign that you're in a way viewing the situation as something like don't let a good crisis go to waste and you feel like you can kind of level set and right-size and still kind of have the same vision for the company remain intact, it's just delayed a little bit? Sorry, that was a lot, but just want to kind of make sure we understand the logic here.

Yes, Doug, that's a great question. I believe that during challenging times, it's essential to maintain focus. It pushes teams to work more efficiently, and practically, we need to align resources with revenues to ensure sustainability. There are three main areas to address: driving revenue growth, improving gross margins, and reducing costs. When we initiated this project, I highlighted our capability to develop multiple platforms at once, supported by a significant R&D budget. We've already made considerable progress on next-generation products alongside Revio. This indicates that our benchtop system is advancing well, and we're utilizing technologies from Revio to enhance its performance. Additionally, we've been working on high-throughput long-read capabilities for some time, and these projects are underway. With some recent reductions, we're acknowledging the progress we've made and assuring that it won't hinder our product timelines. I've put significant thought into managing this situation. The reductions have been applied evenly across G&A, commercial, and R&D. Our aim is to streamline operations, enhance flexibility, and accelerate our pace. Over the past few years, we've built the necessary infrastructure to scale the business, allowing us to monitor revenues, manage customers, and drive marketing efforts effectively. This infrastructure enables us to lower costs across the company. Importantly, I believe we haven't cut so deeply that it jeopardizes our product portfolio. While some investments may be temporarily reduced, we're committed to developing a diverse product range, which we see as vital for a strong business. We're also focused on ensuring exceptional customer experiences. Our priorities during these reductions have been to prioritize customer satisfaction, improve our commercial execution, and develop our product portfolio, which we believe can generate over $500 million in revenue. It may not come as quickly as we previously hoped, but we remain confident in this vision. I appreciate your question and understand your concerns. However, I believe our current strategy is sharply focused. The cost reductions position us well to achieve cash flow breakeven with modest revenue growth, which is crucial in today's different market environment.

The next question comes from Sung Ji Nam with Scotiabank. For your benchtop long-read sequencer under development, Christian, appreciate that, that could alleviate some of the capital spending constraints in the current environment. But was curious what the overlap might be there for the addressable market. You mentioned a 1,000 or so labs, so with your existing customer base. Are the two segments meaningfully differentiated? And then over the longer term, how do you see the benchtop versus high-throughput segments evolving for long-read sequencing? Could it kind of mirror what we're seeing currently for the short-read market? Or do you anticipate something different?

Yes, those are excellent questions. Thank you for asking them. First, we believe there are over 1,000 potential customers for the benchtop long-read system. There may be some overlap between Revio and the benchtop system within our product offerings. However, typically, when a customer requires a high-throughput system but doesn't yet have the demand for it, they might purchase the lower throughput system. Within a reasonable timeframe, usually within 24 months, they often upgrade. This approach is effective for securing long-term customer relationships with future upsell potential. We have observed similar patterns in other cases where customers start with a less expensive device and eventually transition to a higher throughput system. I believe that's the situation here as well. The specifications for the long-read system, which we have yet to reveal, are distinct from Revio, so I don't expect significant cannibalization. We believe the benchtop system will be strong in the clinical markets, especially in smaller clinical labs, although perhaps not in the highest throughput environments. It will have various applications in these labs. When discussing the benchtop system with our high-throughput clients, every one of them has expressed interest in having the benchtop system alongside their Revio, so they can conduct experiments that are better suited for the benchtop system, offering them that flexibility. Thus, we foresee many high-throughput labs operating both systems. This trend is evident across the industry, where numerous customers use different models from the same company, utilizing the same technology but at various throughput levels for different purposes. As for the potential impact of the benchtop long-read system on our short-read opportunities, I don't believe it will affect us negatively. Our focus in short reads is on niche applications, where the benchtop long-read system will likely have limited strategic relevance. Therefore, I anticipate that these two segments will remain quite distinct.

The next question is from Luke Sergott with Barclays.

This is Sam standing in for Luke. Thank you for the questions. You previously mentioned that some advantages from the Revio promotion would begin to materialize in the second quarter and should be fully realized by the year's end. How do you anticipate this promotion will influence the timing of placements this year? Do you expect more activity in the second quarter considering when the promotion started? Also, you indicated that there were delays in samples affecting sequencing volumes this quarter for some major customers. Can you provide more details on that? Did these delays stem from POPSEQ projects?

Yes, that's a good question. When considering the promotions, they are generating new demand, which takes time to develop, and they may push the middle of the sales funnel closer to a decisive point. I wouldn't be surprised if the promotions start having a positive effect in the second quarter and continue throughout the year. However, it's also possible that their largest impact will be felt in the latter half of the year due to the nature of the sales cycles we've been experiencing. These extended sales cycles might get some customers over the finish line and shorten the cycle a bit. While we're not providing specific guidance for Q2 today, I believe the environment remains challenging, but I expect the second half of the year will improve compared to the first half. This outlook is based on where we see our sales funnels and the fact that larger-scale projects should be operational during the second half of the year. Regarding sample delays, some are linked to these larger population-scale projects, and I expect some of them to commence in the second quarter. For instance, the Singapore project is set to begin this quarter, the All of Us project is ongoing, and the veterans' MVP project is making progress. The Estonia project is ramping up quickly; we've installed the systems, and the team is well-trained and capable. We're quite excited about that project and hope it will fully ramp up this quarter and grow throughout 2024. Overall, while the second half of the year looks much more promising than Q2, we are still working on building our sales funnels and enhancing our execution from Q1.

I think one other thing that I'll add is, Sam, if you see in the earnings presentation, we had included a histogram of our installed base and what is across the horizontal axis was the utilization of the instruments in our installed base. But a key driver of that utilization, what you'll notice in the metric below that is that the month or the age in which that instrument was installed and how long it's been in installation is also a driver. So one of the things that we fully expect to happen is that the low utilization, which actually have been installed more recently, are going to start to move to the right. And that's going to help to grow our consumables revenue going forward.

Yes. That's a good point, Susan.

The next question is from Tejas Savant with Morgan Stanley.

Christian, sort of sticking with the needle threading and pipeline pruning theme here. So I want to start with the COGS side, right? So you talked about some good cost cuts on both the Revio unit as well as consumables. Can you just share how much will be passed on to customers via further price cuts and promotions and so on, and how much goes towards better margins to get you to that cash flow breakeven target for 2026? And then on the pipeline, just taking a different tack on some of those earlier questions, I know you mentioned work on that next-gen SMRT Cell for the ultra-high throughput long-read instrument. But in a sense, I mean, is more long-read capacity in the market really the priority that you need to solve for when it sounds like, if anything, the fact that there's too much long-read capacity is what's hamstringing sales here a little bit beyond just the macro? And maybe the solution is helping those applications for long-read mature and scale versus just place more boxes. I think you alluded to some of that on the commercial org side of things, but perhaps you can just elaborate on what you plan to do differently there?

Thank you, Tejas, for your questions. To address the cost reductions first, we have been focused on lowering the production costs of Revio. We are becoming more efficient in manufacturing and have shifted some outsourced work back in-house, which reduces expenses. Improvements in our supply chain are also helping to lower costs. At the same time, we've enhanced our software and technology, allowing us to decrease the power requirements in our instruments. This means we can procure cheaper GPUs, which will help us progress further. We've started seeing some benefits from these changes in the second quarter, and we expect that to continue throughout the year. Depending on the circumstances, some cost savings will be passed on to customers while other portions will enhance our margins. I don’t have a precise breakdown at the moment as it varies by customer. However, we are certainly leveraging these improvements to boost our gross margins and facilitate faster installation and availability of Revio consumables, which should ultimately benefit our margins long-term. Regarding the $25 million investment, we are making significant efficiency improvements, and our yields are improving, allowing us to reduce costs. These enhancements will simplify our strategy and enable us to set prices that bolster our gross margin. A substantial part of these improvements is reflected in our gross margin increase, which is promising. On the pipeline front, the next-generation SMRT Cell is crucial for our company. I acknowledge there's currently more long-read capacity available than ever before, and customers are beginning to absorb it. It will take some time, as mentioned in my earlier comments. However, we must also plan for the future. The development of the next-generation SMRT Cell has been ongoing for several years, and we are nearing the completion of its development. Once we finalize the SMRT Cell, we can determine the timing for developing the accompanying system and its market launch. It's vital to have that core technology ready. We are prioritizing investments in it now because we are close to completion and want to maintain relationships with our external partners. This will also provide the flexibility to decide on the launch of an ultra-high throughput system based on market conditions.

The final question tonight comes from Rachel Vatnsdal with JPMorgan.

This is Rachel from JPMorgan. I wanted to quickly ask about the Revio backlog. At the end of the fourth quarter, you mentioned that the total product backlog was $19 million, most of which was Revio. Can you clarify the 13 Revios that slipped in the quarter compared to the 28 placements, and what that indicates for your backlog at the end of the first quarter?

Susan, you want to take that one?

Yes, I may have overlooked the second part of your question. At the end of last year, we reported a product backlog of $19 million, which we disclose annually rather than quarterly. This year, we expect more book-ship and greater turnover compared to last year, which is typical in the second year of a new product launch. This expectation is factored into our updated revenue guidance. Additionally, we've noticed a trend since the latter half of last year where customers are increasingly placing standing orders for consumables, which has been positive. When customers purchase the Revio instruments, some are opting to order consumables with a specified shipping schedule. Furthermore, we have not fulfilled the entire backlog for instruments, and we intend to sustain instrument backlogs throughout the year. This context is important for understanding our guidance.

Great. All right. Thank you, everybody for joining us today. That's going to conclude our call for today and we look forward to connecting with you throughout the quarter and updating you on our Q2 results later this summer. Have a good one.

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect your lines.